ECMT2 Additional Achievements

Moving into the seventh year, the Endometrial Cancer Molecularly Targeted Therapy Consortium (ECMT2) investigators continue to conduct informative research regarding biomarkers in endometrial cancer. This year three oral plenary abstracts and several posters were presented at the SGO Winter Meeting January 30 to February 1, 2025 in Whistler Canada.

Dr. Vue, a Gynecologic Oncology fellow at Alleghany Health Network, presented her abstract, "Concordance and frequency of TP53 protein expression and gene sequence in mismatch repair proficient (pMMR) and POLE wild-type endometrial cancer: An Endometrial Cancer Molecularly Targeted Therapy Consortium database study."

Two other oral abstract presentations included Dr. Bobby May, Duke University, Ob/Gyn resident, "FRα, B7-H4, & HER2 expression in endometrial cancer: Assessing the promise of antibody drug conjugate therapies.” and Dr. Glenn Boyles, UNC-Chapel Hill Gynecologic Oncology fellow, "Differences in the molecular profiles of endometrial cancer between White and Black women: a real world ECMT2 Consortium cohort study".

Margaret Klein, George Washington University, and Sarah Provencher, Duke University, are medical students and presented their posters entitled "Association between race, ethnicity, and mode of mismatch repair mutations on molecular expression and cancer outcomes: A real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study" and "The relationship between chemotherapy response score and molecular subtyping of advanced endometrial cancer", respectively.

The work of the consortium has resulted in five community awareness events, 15 abstract presentations, three nationally recognized awards, and three subsequent research grants.

Three national award-winning abstracts including:
• "Genomic alterations, molecularly targeted therapy and race: Real world data from the Endometrial Cancer Molecularly Targeted Therapy Consortium (LBA 8)"
o SGO Annual Meeting 2022 Best Clinical Science Award
• "TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes"
o SGO Winter Meeting 2023 Buck and Betsy Peters Best Oral Presentation Award
• "Concordance and frequency of TP53 protein expression and gene sequence in mismatch repair proficient (pMMR) and POLE wild-type endometrial cancer: An Endometrial Cancer Molecularly Targeted Therapy Consortium (ECMT2) database study"
o SGO Winter Meeting 2025 Buck and Betsy Peters Best Oral Presentation Award.

Completed Manuscripts:
1. Duke (Secord): Genomic alterations, molecularly targeted therapy and race: Real world data from the Endometrial Cancer Molecularly Targeted Therapy Consortium (LBA 8)
• DOI: 10.1016/S0090-8258(22)01301-4
2. NYU (Lee/Pothuri): The association of tumor mutational burden, microsatellite stability, and mismatch repair deficiency in an endometrial cancer patient cohort (194)
• DOI: https://doi.org/10.1016/S0090-8258(22)01421-4
3. Duke (Whelan): TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes
• DOI: 10.1016/j.ygyno.2023.09.009
4. University of Colorado (Dr. Corr): PR023/#503 Evaluation of the combination Lenvatinib and Pembrolizumab in Endometrial Cancer; A real world multi-institutional review of practice patterns, efficacy and tolerability
• DOI: https://doi.org/10.1136/ijgc-2023-IGCS.65

International Gynecologic Cancer Society Annual Meeting in Seoul, South Korea, Angeles Alvarez Secord, MD, MHSc, presented real-word data — from the DCI-based Endometrial Cancer Molecularly Targeted Therapy Consortium she leads — on the pembrolizumab and lenvatinib prescribing patterns sub-study for endometrial cancer patients. The sub-study was led by Drs. Brad Corr (University of Colorado) and Stephanie Gaillard (Johns Hopkins University).
Click here to read and watch Dr. Secord's ESMO Reflections on Endometrial Cancer.

ECMT2 Subprojects Presented: